ReviewFrontiers in cell and developmental biology2026
JMJD5: a multifunctional regulator in development, homeostasis, and cancer.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
JmjC-domain-containing oxygenases are conserved epigenetic regulators whose dysfunction is closely associated with various human diseases. JMJD5, a key member of the JmjC-Domain-Only subfamily, has multiple enzymatic activities and modulates various vital physiological and pathological processes via catalytic and non-catalytic pathways. JMJD5 also displays striking tissue-specific duality in cancer: it is frequently overexpressed and acts as an oncogene in breast, prostate, and oral squamous cell carcinomas, yet is downregulated and functions as a tumor suppressor in lung, hepatocellular, and pancreatic cancers. This functional heterogeneity is closely linked to its interacting protein networks and the tumor microenvironment. Pan-cancer analyses further reveal that JMJD5 expression correlates with patient prognosis and disease progression in multiple malignancies, highlighting its potential as a prognostic biomarker. This review systematically integrates current knowledge on JMJD5 structure, enzymatic activities, physiological functions, and cancer-associated mechanisms, identifies critical research gaps, and discusses future directions for translating JMJD5 into clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.